TY - JOUR
T1 - Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer
AU - Bianchini, Giampaolo
AU - Iwamoto, Takayuki
AU - Qi, Yuan
AU - Coutant, Charles
AU - Shiang, Christine Y.
AU - Wang, Bailang
AU - Santarpia, Libero
AU - Valero, Vicente
AU - Hortobagyi, Gabriel N.
AU - Symmans, W. Fraser
AU - Gianni, Luca
AU - Pusztai, Lajos
PY - 2010/11/1
Y1 - 2010/11/1
N2 - Different kinases are expressed in different clinical subsets of breast cancer. In this study, we assessed kinase expression patterns in different clinical subtypes of breast cancer, evaluated the prognostic and predictive values of kinase metagenes, and investigated their functions in vitro. Four hundred twenty-eight protein kinases in gene expression data were examined from 684 cases of breast cancer and 51 breast cancer cell lines to identify kinase expression patterns. We tested the prognostic value of kinase metagenes in 684 node-negative patients who received no adjuvant therapy and the predictive value in 233 patients who received uniform neoadjuvant chemotherapy. Twelve kinases were overexpressed in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 7 in HER2+, and 28 in ER -/HER2- cancers, respectively. We examined the functional role of 22 kinases overexpressed in ER-/HER2- cancers using siRNA. Downregulation of these kinases caused significant subtype-specific inhibition of cell growth in vitro. Two robust kinase clusters, including an immune kinase cluster and a mitosis kinase cluster, were present in all clinical subgroups. High mitosis kinase score was associated with worse prognosis but higher pathologic complete response (pCR) in ER+/HER2- cancers, but not in ER-/HER2- or HER2+ cancers, in univariate and multivariate analyses including other genomic predictors (MammaPrint, genomic grade index, and the 76-gene signature). Conversely, higher immune kinase score was associated with better survival in ER +/HER2- and HER2+ tumors and also predicted higher probability of pCR in HER2+ cancers. Taken together, our results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype.
AB - Different kinases are expressed in different clinical subsets of breast cancer. In this study, we assessed kinase expression patterns in different clinical subtypes of breast cancer, evaluated the prognostic and predictive values of kinase metagenes, and investigated their functions in vitro. Four hundred twenty-eight protein kinases in gene expression data were examined from 684 cases of breast cancer and 51 breast cancer cell lines to identify kinase expression patterns. We tested the prognostic value of kinase metagenes in 684 node-negative patients who received no adjuvant therapy and the predictive value in 233 patients who received uniform neoadjuvant chemotherapy. Twelve kinases were overexpressed in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 7 in HER2+, and 28 in ER -/HER2- cancers, respectively. We examined the functional role of 22 kinases overexpressed in ER-/HER2- cancers using siRNA. Downregulation of these kinases caused significant subtype-specific inhibition of cell growth in vitro. Two robust kinase clusters, including an immune kinase cluster and a mitosis kinase cluster, were present in all clinical subgroups. High mitosis kinase score was associated with worse prognosis but higher pathologic complete response (pCR) in ER+/HER2- cancers, but not in ER-/HER2- or HER2+ cancers, in univariate and multivariate analyses including other genomic predictors (MammaPrint, genomic grade index, and the 76-gene signature). Conversely, higher immune kinase score was associated with better survival in ER +/HER2- and HER2+ tumors and also predicted higher probability of pCR in HER2+ cancers. Taken together, our results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype.
UR - http://www.scopus.com/inward/record.url?scp=78449290946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78449290946&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-10-1039
DO - 10.1158/0008-5472.CAN-10-1039
M3 - Article
C2 - 20959472
AN - SCOPUS:78449290946
SN - 0008-5472
VL - 70
SP - 8852
EP - 8862
JO - Cancer Research
JF - Cancer Research
IS - 21
ER -